Corvus Pharmaceuticals, Inc. (CRVS) Ownership
CRVS ownership summary
as of October 17, 2026- Institutions
- 85.8% of shares outstanding
- Insiders
- 3.51% of shares outstanding
- Shares outstanding
- 84.1M
- Float
- 72.8M shares available to trade
- Short interest
- 24.05% 17.8M shares short
- Days to cover
- 15.44 short interest up 3.6% vs prior month
- Institutions 85.82%
- Insiders 3.51%
- Other investors 10.68%
CRVS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Orbimed Advisors LLC | 8.52% | 7.2M | $68.2M | — | June 30, 2026 |
| 2 | BlackRock Inc | 8.49% | 7.1M | $68.0M | +978,389 (+15.9%) | June 30, 2026 |
| 3 | State Street Corp | 5.32% | 4.5M | $42.6M | +908,099 (+25.5%) | June 30, 2026 |
| 4 | T. Rowe Price Associates, Inc. | 4.50% | 3.8M | $36.1M | +871,826 (+29.9%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 3.91% | 3.3M | $31.3M | +58,172 (+1.8%) | June 30, 2026 |
| 6 | Adams Street Partners LLC | 3.89% | 3.3M | $31.2M | — | June 30, 2026 |
| 7 | Vivo Capital, LLC | 3.34% | 2.8M | $26.7M | — | June 30, 2026 |
| 8 | Wellington Management Company LLP | 3.25% | 2.7M | $26.0M | +413,115 (+17.8%) | June 30, 2026 |
| 9 | Perceptive Advisors LLC | 3.17% | 2.7M | $25.4M | +375,000 (+16.4%) | June 30, 2026 |
| 10 | Deep Track Capital, LP | 2.96% | 2.5M | $23.7M | +400 (+0.0%) | June 30, 2026 |
| 11 | BRAIDWELL LP | 2.53% | 2.1M | $20.2M | +373,500 (+21.3%) | June 30, 2026 |
| 12 | Geode Capital Management, LLC | 2.20% | 1.9M | $17.6M | +140,918 (+8.2%) | June 30, 2026 |
| 13 | Foresite Capital Management VI LLC | 2.18% | 1.8M | $17.4M | — | June 30, 2026 |
| 14 | The Goldman Sachs Group Inc | 1.87% | 1.6M | $15.0M | +35,543 (+2.3%) | June 30, 2026 |
| 15 | Hood River Capital Management LLC | 1.87% | 1.6M | $15.0M | +236,696 (+17.7%) | June 30, 2026 |
| 16 | Morgan Stanley - Brokerage Accounts | 1.60% | 1.3M | $12.8M | −1.2M (−46.2%) | June 30, 2026 |
| 17 | Boxer Capital Management, LLC | 1.31% | 1.1M | $10.5M | — | June 30, 2026 |
| 18 | Catalio Capital Management, LP | 1.28% | 1.1M | $10.3M | +188,955 (+21.2%) | June 30, 2026 |
| 19 | Millennium Management LLC | 1.25% | 1.0M | $10.0M | +181,623 (+21.0%) | June 30, 2026 |
| 20 | Vanguard Portfolio Management, LLC | 0.97% | 815K | $7.8M | +144,855 (+21.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 4.9M shares and 1 cut 1.2M.
CRVS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.86% | 2.4M | $22.9M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.17% | 1.8M | $17.4M | −34,850 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 1.97% | 1.7M | $15.8M | −19,136 (−1.1%) | September 30, 2026 |
| 4 | T. Rowe Price New Horizons | 1.04% | 878K | $8.4M | −35,874 (−3.9%) | August 31, 2026 |
| 5 | T. Rowe Price Integrated US Sm Gr Eq | 0.95% | 802K | $7.6M | — | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.88% | 741K | $7.0M | +5,645 (+0.8%) | July 31, 2026 |
| 7 | Hood River Small-Cap Growth Instl | 0.84% | 707K | $6.7M | −36,901 (−5.0%) | June 30, 2026 |
| 8 | iShares Russell 2000 Growth ETF | 0.71% | 597K | $5.7M | −756 (−0.1%) | September 30, 2026 |
| 9 | iShares Biotechnology ETF | 0.59% | 499K | $4.8M | −3,784 (−0.8%) | September 30, 2026 |
| 10 | Schwab US Small-Cap ETF™ | 0.47% | 395K | $3.8M | +261 (+0.1%) | September 30, 2026 |
| 11 | Vanguard Russell 2000 ETF | 0.46% | 389K | $3.7M | +9,400 (+2.5%) | August 31, 2026 |
| 12 | Fidelity Extended Market Index | 0.43% | 363K | $3.5M | −1,949 (−0.5%) | August 31, 2026 |
| 13 | Vanguard Explorer Inv | 0.35% | 291K | $2.8M | +290,675 (0.0%) | June 30, 2026 |
| 14 | MEDICAL BioHealth EUR Acc | 0.30% | 254K | $2.4M | +54 (+0.0%) | August 31, 2026 |
| 15 | SEB Läkemedelsfond A (SEK) | 0.27% | 227K | $2.2M | — | August 31, 2026 |
| 16 | iShares Micro-Cap ETF | 0.24% | 201K | $1.9M | −1,385 (−0.7%) | September 30, 2026 |
| 17 | Vanguard Health Care ETF | 0.23% | 192K | $1.8M | +840 (+0.4%) | August 31, 2026 |
| 18 | Emerald Growth A | 0.22% | 189K | $1.8M | — | August 31, 2026 |
| 19 | Principal SmallCap Growth I Instl | 0.21% | 179K | $1.7M | +2,477 (+1.4%) | August 31, 2026 |
| 20 | Northwestern Mutual Ser Small Cap Gr Stk | 0.21% | 178K | $1.7M | +156,144 (+716.3%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CRVS insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-06-27 | Peter A Thompson | Sell | $4.16 | 1,176,332 | $4.9M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CRVS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CRVS
Institutional investors own 85.8% of Corvus Pharmaceuticals's shares and insiders 3.51%. The largest holder is Orbimed Advisors LLC with 8.52% of the shares (7.2M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 1 reduced their stake in the latest filings. Short interest is 24.05% of the float, or 15.44 days of average trading volume. The share count rose 25,320.1% since 2014.
Related: CRVS analyst forecast, CRVS key metrics. See the CRVS stock overview for the latest quote and news.
CRVS ownership FAQ
Who owns the most Corvus Pharmaceuticals stock?
The largest shareholders of Corvus Pharmaceuticals are Orbimed Advisors LLC (8.52%), BlackRock Inc (8.49%), State Street Corp (5.32%), T. Rowe Price Associates, Inc. (4.50%), Vanguard Capital Management, LLC (3.91%).
What percentage of Corvus Pharmaceuticals is owned by institutions?
Institutions hold 85.8% of Corvus Pharmaceuticals's shares outstanding; insiders hold 3.51%.
Which funds own Corvus Pharmaceuticals?
The largest fund holders of Corvus Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (2.86%), State Street® SPDR® S&P® Biotech ETF (2.17%), iShares Russell 2000 ETF (1.97%), T. Rowe Price New Horizons (1.04%), T. Rowe Price Integrated US Sm Gr Eq (0.95%).
What is Corvus Pharmaceuticals's short interest?
17.8M shares of Corvus Pharmaceuticals were sold short, 24.05% of the float; at the average daily volume it would take 15.44 days to cover.
Are insiders buying or selling Corvus Pharmaceuticals?
Of the latest 1 reported insider transactions in Corvus Pharmaceuticals (since June 27, 2025), 0 were purchases and 1 were sales.
How many shares of Corvus Pharmaceuticals are outstanding?
Corvus Pharmaceuticals has 84.1M shares outstanding, of which 72.8M are in the public float.